Candidates for Systemic Therapy for Psoriasis
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB05676 | Apremilast | A non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis. |
| DB16650 | Deucravacitinib | A TYK2 inhibitor being investigated as a treatment for psoriasis. |
| DB00095 | Efalizumab | A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. |
| DB14762 | Risankizumab | An interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults. |
| DB14004 | Tildrakizumab | An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. |
| DB05679 | Ustekinumab | A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB00095 | Efalizumab | 4 | Completed | 1 |